Journal Mobile Options
Table of Contents
Vol. 9, Suppl. 2, 1998
Issue release date: July 1998

The Bayer Activities of Daily Living Scale (B-ADL)

Hindmarch I. · Lehfeld H. · de Jongh P. · Erzigkeit H.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The Bayer Activities of Daily Living Scale (B-ADL) has been developed on an international basis to assess deficits in the performance of everyday activities. The scale’s main target group is community dwelling patients who suffer mild cognitive impairment or mild-to-moderate dementia. It comprises 25 items and takes the form of a questionnaire to be completed by a caregiver or other informant sufficiently familiar with the patient. Statistical, clinical and domain-related criteria were used to select items from among a large number of activities of daily living (ADL) questions field tested in pilot studies in the USA, Germany, UK, Russia and Greece. The items included in the B-ADL have been chosen for their sensitivity to cognitive impairment, simplicity of concept, international applicability and their relevance to patients coping with the demands of everyday life. The scale uses items which reflect a wide range of domains. On account of its brevity, it is thought especially suitable for application within a GP and primary care context for both screening a patient’s ADL capacities as well as for documentation of treatment effects and the progress of dementia. This paper focuses on a description of the scale and its application.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Rubin EH, Morris C, Grant EA, Vendegna T: Very mild senile dementia of the Alzheimer type. I: Clinical assessment. Arch Neurology 1989;46:379–382.

    External Resources

  2. Morris JC, McKeel DW, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L: Very mild Alzheimer’s disease: Informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology 1991;41:469–478.
  3. Curran S, Russell E, Burns A: Treatment of cognitive deficits in Alzheimer’s disease. Prim Care Psychiatry 1997;3,151–161.
  4. Jorm AF, Korten AE: Assessment of cognitive decline in the elderly by informant interview. Br J Psych 1988;152:209–213.
  5. Committee for Proprietary Medicinal Products (CPMP): Note for guidance on medicinal products in the treatment of Alzheimer’s disease. The European Agency for the Evaluation of Medicinal Products. London, Human Medicines Evaluation Unit, 1997.
  6. Gauthier S, Bodick N, Erzigkeit H, Feldman H, Geldmacher DS, Huff J, Mohs R, Orgogozo JM, Rogers S: Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord 1997;11(suppl 3):6–7.
  7. Leber P: Guidelines for the clinical evaluation of antidementia drugs. First draft. Rockville, Food and Drug Administration, 1990.
  8. Clinical Research Working Group from the Pharmaceutical Industry on Dementia: Recommendations for clinical drug trials in dementia. Dementia 1990;1:292–295.
  9. Poon LW: On the paradox of improving sensitivity of ADL scales for the detection of behavioural changes in early dementia. Int Psychogeriatr 1994;6:171–177.
  10. Schmidt-Gollas N, Erzigkeit H: Ways of constructing a therapy sensitive scale for the assessment of ADL aspects in cognitively impaired elderly patients; in Bergener M, Belmaker R, Tropper H (eds): Pharmacotherapy for the elderly. Research and Implications. New York, Springer, 1993, pp 119–131.
  11. Erzigkeit H, Overall JE, Stemmler M, Steinwachs KC, Lehfeld H, Hulla FW: Assessing behavioral changes in antidementia therapy: Perspectives of an international ADL-project; in Bergener M, Brocklehurst J, Finkel S (eds): Aging, Health, and Healing. New York, Springer, 1995, pp 359–374.
  12. Finkel S, Bergener M, Stemmler M, Hulla F, Overall JE: The use of clinical experience to stage the severity of functional impairments in Alzheimer’s disease. Hum Psychopharmacol 1996;11:439–449.

    External Resources

  13. Lehfeld H, Reisberg B, Finkel S, Kanowski S, Wied V, Pittas J, Tsolaki M, Robert PH, Hulla F, Heininger K, Erzigkeit H: Informant-rated Activities-of-Daily-Living (ADL) Assessments: Results of a study of 141 items in the USA, Germany, Russia, and Greece from the International ADL Scale Development Project. Alzheimer Dis Assoc Disord 1997;11(suppl 4): S39–S44.
  14. Reisberg B: The ADL-IS: History and Progress. Presentation at the eighth congress of the International Psychogeriatric Association (IPA). 1996, Jerusalem, Israel, August 17–22.
  15. Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF: Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 1992;40:1129–1134.
  16. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S, Alzheimer’s Disease Cooperative Study: An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord;11(suppl 2):S33–S39.
  17. Lundin-Olsson l, Nyberg L, Gustafson Y: ‘Stops walking when talking’ as a predictor of falls in elderly people. Lancet 1997, 349:617.
  18. Herberg KW, Steinwachs KC, Woelk H, Bernhardt T: Alltagskompetenz älterer Patienten wächst unter einer Therapie mit Nimodipin. Extracta Geriatrica 1997;3:20–25.
  19. Heininger K, Keppel Hesselink JM: The role of the Bayer ADL-International Scale in the management of dementia patients. Presentation at the eighth congress of the International Psychogeriatric Association (IPA). 1996, Jerusalem, Israel, August 17–22.
  20. Brislin RW: The wording and translation of research instruments; in Lonner W, Berry J (eds): Field methods in Cross-Cultural Research. Beverly Hills, Sage, 1986, pp 137–164.
  21. Sartorius N, Kuyken W: Translation of health status instruments; in Orley J, Kuyken W (eds): Quality of Life Assessment in Health Care Settings. Berlin, Springer, 1994, pp 3–18.
  22. Reisberg B, Ferris SH, deLeon MJ, Crook T: The Global Deterioration Scale for the assessment of primary degenerative dementia. Am J Psych 1982;139:1136–1139.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50